This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Breast Cancer
and you are
between 40 and 65
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

In recent years, the increasing number of breast cancer patients shows the fact breast cancer is one of the most common cancers in women in China. However, the mortality rate has seen a dramatic decline mainly due to early detection of breast cancer and the use of effective multimodel treatment. Recent studies suggest breast cancers are heterogeneous and recognized by biological subtypes, which lead to markedly different clinical outcome. Adjuvant chemotherapy is widely used in the treatment for primary breast cancer patients. Different types of breast cancer cells are sensitive to different types of drugs.There is no data to support the information about the adjuvant chemotherapy regimens for different subtypes breast cancer patients, especially for Chinese women. The investigators hypothesized to confirm the possibility of finding the adjuvant chemotherapy aimed to different subtypes of breast cancer.

Provided treatments

  • Drug: Docetaxel Cyclophosphamide
  • Drug: Cyclophosphamide Fluorouracil Epirubicin Docetaxel
  • Drug: Epirubicin Cyclophosphamide Paclitaxel

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01314833. The sponsor of the trial is Fudan University and it is looking for 3200 volunteers for the current phase.
Official trial title:
A Randomized Prospective Open Multicentric Phase III Clinical Trial Compared TC, FEC100 Followed by Docetaxel and EC90 Followed by Paclitaxel as Adjuvant Chemotherapy for Chinese Primary Breast Cancer Patients